Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

In their concluding remarks, the expert panel shares insights and provides recommendations to help practicing clinicians optimize atopic dermatitis patient care.

Episodes in this series

Video features 3 KOLs

EP. 1 Tackling Key Concerns in Atopic Dermatitis + Biologic Use

Video features 3 KOLs

EP. 2 Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

Video features 3 KOLs

EP. 3 Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

Video features 3 KOLs

EP. 4 Experts Discuss Long-Term Effects and Monitoring in AD Therapy

Video features 3 KOLs

EP. 5 Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

Video features 3 KOLs

EP. 6 The Patient Journey: Effectively Managing AD Itch Early On

Video features 3 KOLs

EP. 7 Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

Video features 3 KOLs

EP. 8 Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

Please provide your final thoughts from each of you, including key insights that you’re taking away from this discussion.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Anita Kumar, MD, of MSKCC in Basking Ridge, New Jersey, highlighted advances in treatment of transplant-ineligible mantle cell lymphoma, including chemotherapy-free options. | Image: MSKCC

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

June 20th 2026

Myeloproliferativedisorder | Image Credit: © ibreakstock-stock.adobe.com

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

ByMaggie L. Shaw

June 19th 2026

Principal investigator Sara A. Hurvitz, MD, said results with the gedatolisib combinations show they could be the new standard of care in HR+/HER2- advanced breast cancer. | Image: Fred Hutch

In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer

June 19th 2026

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 19th 2026

Fibrosis Belongs at Center of MASH End Points: Zobair M. Younossi, MD

ByLaura Joszt, MA,Zobair M. Younossi, MD

June 19th 2026

Trending on AJMC

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

Defunding Co-Payment Assistance Disrupted nAMD Care

Study Finds Flaw in Method for Key Oncology Value-Based Care Model